Brain Backups is developing AptaMark, a new contrast agent that uses aptamers to image dopamine receptors in the brain at a resolution of 1 micron, far greater than current MRI technology. AptaMark aims to provide an early, accurate, and objective diagnostic test for Parkinson's disease by directly tracking neurodegeneration in the substantia nigra. It could also be used to differentiate Parkinson's subtypes and monitor disease progression, representing a large market opportunity as diagnosis and treatment of Parkinson's increases. Brain Backups is seeking $2.5 million to further optimize and validate AptaMark.
On the ground experiences & challenges of a connected diagnostics GxAlert in ...SystemOne
This document summarizes Nigeria's experience implementing the GxAlert connectivity tool for GeneXpert machines. Key points include:
- GxAlert allows GeneXpert machines to report test results in real-time via a secure online network, making results actionable within the health system.
- Over 200 GeneXpert machines in Nigeria are now connected via GxAlert. This enables real-time notification of test results, machine errors, and stock levels.
- Challenges include inconsistent internet availability, incomplete primary data, and a need to better integrate GxAlert with other electronic reporting systems like e-TB Manager and DHIS2. Support is also needed to sustain connectivity and uniquely identify patients.
Disrupting Conventional Therapies with Digital TherapiesMedullan
Join this webinar to learn about:
Bio 2.0 - what it is, what problems it aims to address, why it's important now, and what leading indicators of its potential have we seen in the market.
The new clinical development patterns that will emerge to help Life Science companies bring digital therapies and solutions to market in a predictable and sustainable way.
The potential roadblocks, the regulatory ambiguity, and its potential for clarity as these patterns take hold.
Many will still find it hard to decide what initiatives to scale up and how to determine which pathways to follow, as it’s unclear what digital success will look like five years from now. This series aims to bring innovators and industry leaders together to imagine what success could be and discuss ways to get there.
ASLM- Alere: Importance of Quality SystemsSystemOne
This document discusses the importance of quality systems and connectivity for decentralized HIV testing. It notes that point-of-care testing presents challenges for quality control compared to centralized laboratories due to harsher environments, less skilled operators, and fewer resources. However, connected diagnostic platforms can help by providing continuous quality monitoring, internal quality control, external quality assessment, and key performance/quality indicators. The document highlights a pilot project in Zimbabwe using an integrated laboratory network for automated quality monitoring and external quality assessment reporting. It concludes that connectivity is essential to ensure successful scale-up of testing and maximize return on investment as testing expands to more facilities.
This document discusses medical device customer segments. It notes that medical device markets are often multi-sided, involving patients, physicians, hospitals/practices, payors, and regulators. It emphasizes the importance of understanding reimbursement and following the money to identify who the real customers are in a given market. The document provides an overview of physicians, patients, hospitals, and medical device companies as potential customer segments and discusses their key pains and gains. It also outlines different types of medical device markets and what they typically mean for startups versus large acquirers.
Luminate is a drug being developed by Allegro Ophthalmics to treat retinal diseases. It works through a novel anti-integrin mechanism of action compared to existing anti-VEGF drugs. Phase 2 studies showed Luminate had a 65% efficacy rate in resolving vitreomacular traction, a robust safety profile, and durability of at least 3 months in treating diabetic macular edema and wet age-related macular degeneration. Ongoing phase 2b studies are further evaluating Luminate's potential to treat diabetic macular edema, proliferative vitreoretinopathy, and as an alternative to anti-VEGF drugs with longer duration of effect.
On the ground experiences & challenges of a connected diagnostics GxAlert in ...SystemOne
This document summarizes Nigeria's experience implementing the GxAlert connectivity tool for GeneXpert machines. Key points include:
- GxAlert allows GeneXpert machines to report test results in real-time via a secure online network, making results actionable within the health system.
- Over 200 GeneXpert machines in Nigeria are now connected via GxAlert. This enables real-time notification of test results, machine errors, and stock levels.
- Challenges include inconsistent internet availability, incomplete primary data, and a need to better integrate GxAlert with other electronic reporting systems like e-TB Manager and DHIS2. Support is also needed to sustain connectivity and uniquely identify patients.
Disrupting Conventional Therapies with Digital TherapiesMedullan
Join this webinar to learn about:
Bio 2.0 - what it is, what problems it aims to address, why it's important now, and what leading indicators of its potential have we seen in the market.
The new clinical development patterns that will emerge to help Life Science companies bring digital therapies and solutions to market in a predictable and sustainable way.
The potential roadblocks, the regulatory ambiguity, and its potential for clarity as these patterns take hold.
Many will still find it hard to decide what initiatives to scale up and how to determine which pathways to follow, as it’s unclear what digital success will look like five years from now. This series aims to bring innovators and industry leaders together to imagine what success could be and discuss ways to get there.
ASLM- Alere: Importance of Quality SystemsSystemOne
This document discusses the importance of quality systems and connectivity for decentralized HIV testing. It notes that point-of-care testing presents challenges for quality control compared to centralized laboratories due to harsher environments, less skilled operators, and fewer resources. However, connected diagnostic platforms can help by providing continuous quality monitoring, internal quality control, external quality assessment, and key performance/quality indicators. The document highlights a pilot project in Zimbabwe using an integrated laboratory network for automated quality monitoring and external quality assessment reporting. It concludes that connectivity is essential to ensure successful scale-up of testing and maximize return on investment as testing expands to more facilities.
This document discusses medical device customer segments. It notes that medical device markets are often multi-sided, involving patients, physicians, hospitals/practices, payors, and regulators. It emphasizes the importance of understanding reimbursement and following the money to identify who the real customers are in a given market. The document provides an overview of physicians, patients, hospitals, and medical device companies as potential customer segments and discusses their key pains and gains. It also outlines different types of medical device markets and what they typically mean for startups versus large acquirers.
Luminate is a drug being developed by Allegro Ophthalmics to treat retinal diseases. It works through a novel anti-integrin mechanism of action compared to existing anti-VEGF drugs. Phase 2 studies showed Luminate had a 65% efficacy rate in resolving vitreomacular traction, a robust safety profile, and durability of at least 3 months in treating diabetic macular edema and wet age-related macular degeneration. Ongoing phase 2b studies are further evaluating Luminate's potential to treat diabetic macular edema, proliferative vitreoretinopathy, and as an alternative to anti-VEGF drugs with longer duration of effect.
The document summarizes updates on corneal cross-linking (CXL) technology from Avedro, including:
1) In March 2015, Avedro received a letter from the FDA requesting further information about equivalency between study devices and commercial systems for CXL to treat keratoconus and ectasia.
2) Agreement was reached on additional measurements required to address the FDA's questions. The application was resubmitted in October 2015.
3) Preliminary data is presented on trials of a new CXL technique called PiXL for treating myopia, keratoconus, and post-cataract refractive error, showing safety and efficacy.
From an Olympic-sized thought-powered light show to your very own brain sensing headband, InteraXon CEO and neuroscientist Ariel Garten speaks to the sensor revolution and to the democratization of brain sensing technology. With the launch of their first consumer-ready product, Muse: the brain sensing headband, Ariel shares how more and more people are turning to brain sensing tech to gain immediate insight and personalized data to track and explore their inner technologies and enable them to do more with their minds than they ever thought possible.
• Ariel Garten - Co-Founder and CEO, InteraXon
New York eHealth Collaborative Digital Health Conference
November 18, 2014
The document discusses developing new radiotracers for positron emission tomography (PET) imaging using green fluorescent protein (GFP) technology. This allows for fast, multi-platform synthesis of short-lived radiotracers for indications like pediatric neuroblastoma and Parkinson's disease. Initial targets are developing the methodology, understanding regulatory processes, and conducting animal and clinical studies. The business model involves selling radiotracers and precursors to radiopharmacies, hospitals, and imaging centers.
Commendo research & consulting GmbH proposes a recommender technology to optimize the drug design process. The technology would speed up development, allow for highly customized drugs, minimize adverse reactions, and increase the probability drugs pass clinical trials. It discovers harmful drug combinations to reduce side effects. There is a large business opportunity in the pharmaceutical industry as developing one drug costs over $800 million and 95% of drugs are rejected. The technology builds an holistic model integrating substance and effect data from all drug development stages. It uses recommender algorithms to predict unknown effects and identify substances with desired effects to develop customized drugs. The company's team previously led the Netflix Prize competition in recommender systems research.
The document proposes developing an affordable portable ultrasound device to enable widespread screening. It would benefit patients through early detection and be convenient for doctors to use like a stethoscope. The founders aim to market the device to various medical specialties. It outlines the product, team, sales strategy, target customers, costs, revenue projections, potential partners, funding needs, and risks. The goal is for the device to become profitable within 4 years of development and regulatory approval.
RM Genetics specialists work with healthcare providers to help them to determine individuals who would benefit from PGx treatment. We partner with labs acroshs the United States to offer the most progressive, gene panel testing in pharmacogenomics. We also have another program testing for hereditary cancer and toxicology. PGX test will provide a comprehensive report based on an individual patient’s genetic makeup that will indicate metabolic rates for defined medications. This information will help clinicians prescribe the right drug at the right dose based on your patient’s DNA profile.
Presentation/demo held at Google Developer Group Oslo DevFest 2014
Abstract:
This talk will show you how to build an Android Wear app. Thomas will start out with a plain notification and show you how to add features until you have a full-fledged card UI. We will discuss the role of the phone and the watch and how to communicate between them. As a case study he will use a prototype for a news alert app he's working on - there will be plenty of code examples and demos.
Thomas Oldervoll has worked 5 years for Google in Mountain View and 9 years for Zenior in Oslo. He likes building things, in particular machine learning, scalable backend systems and Android apps.
The document provides an overview of Android Wear development including basic setup, notifications, layouts, the data layer, and a comparison to WatchKit. It discusses debugging over Bluetooth, using emulators, packaging structures, basic and expanded notifications, backgrounds, remote control, actions, and common layouts. Code examples and resources are provided for key topics like notifications, data transfer, and common UI structures in Android Wear.
Android Wear is Google's attempt to bring unity to the wearable device ecosystem by optimizing Android for wearables. It allows wearables like the Moto 360 and G Watch to provide contextual information, integrate with Google services, offer better health and fitness experiences, and control other devices through features like voice actions and APIs that access device sensors. While competitors include Pebble, Galaxy Gear, and Sony SmartWatch, Android Wear differs in having no device lock-down, supporting native Android development, and using wearables as less intrusive ways to share information and naturally control other technologies.
The document discusses the self-concept, which is one's view of oneself and one's qualities. The self-concept is multidimensional, including the physical, spiritual, social, and inner selves. It is influenced by factors like skills, parents, social contact, and self-motivation. The self-concept can be positive if one evaluates one's qualities positively, or negative if one is dissatisfied. Maintaining a positive self-concept involves self-care, caring for others, positive self-talk, goal-setting, and self-reflection.
In this session, I will give an overview of Android Wear and how to integrate it in your product strategy. We will look at the underlying design principles and discuss a number of use cases for apps that connect to wearable devices. After that, we will take a look at some code examples and learn how to use the Android Wear SDK.
This document provides an overview of Android Wear and how to develop apps for it. Some key points include:
- Android Wear allows developers to extend existing Android notifications and apps to smartwatches.
- Notifications on Android Wear can include additional content, voice input, and actions.
- Apps need to be designed for quick interactions with minimal taps or swipes on small screens.
- The Android Wear SDK allows communicating between phone and watch apps using APIs for nodes, messages, and shared data.
Smartwatches have evolved from simple devices that displayed limited information like calendars and phone connectivity to full-fledged computers on the wrist. Early smartwatches in the 2000s had basic features while models in the 2010s could make calls, send texts, access the internet, and track health data. Modern smartwatches often use touchscreens, pair with smartphones for full functionality, and focus on fitness tracking and health monitoring. Top brands today include Android Wear watches and upcoming models like the Apple Watch, with pricing ranging from $100 to $400. However, smartwatches have yet to achieve mass popularity due to issues with size, battery life, and being perceived more as tech devices than fashion accessories.
Appian Medical Investor Presentation: September 2014Appian Medical
The document describes SnoreSounds, a smartphone app and algorithm that can accurately diagnose obstructive sleep apnea (OSA) using acoustic analysis of snoring sounds. It has the potential to disrupt the sleep diagnostics market by providing an inexpensive, convenient home test. Clinical studies show the algorithm achieves over 90% accuracy compared to in-lab polysomnography tests. The business model involves direct-to-consumer sales of the app as well as licensing the algorithm to partners. Regulatory clearance is underway to allow diagnosis and treatment based on the app results.
Top Brainnovation to improve Brain Health & PerformanceSharpBrains
The three Finalists were:
*Click Therapeutics — pitch by David Klein, Co-Founder & CEO
*AUGMENTx (WINNER) — pitch by Dr. Albert Kwon, Co-Founder & CEO
*Sincrolab — pitch by Ignacio de Ramon, Co-Founder & CEO
*Judged by: Alexandra Morehouse, Chief Marketing Officer at Banner Health; Colin Milner, Founder and CEO of the International Council on Active Aging (ICAA); Danny Dankner, CEO and Co-founder of Applied Cognitive Engineering; Zack Lynch, General Partner at JAZZ Venture Partners
*Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains
*Sarah Lenz Lock, Senior Vice President for Policy at AARP and Executive Director of the Global Council on Brain Health (GCBH)
*Dr. April Benasich, Director of the Baby Lab at the Rutgers Center for Molecular and Behavioral Neuroscience
*Chaired by: Dr. Cori Lathan, Co-Chair of the World Economic Forum’s Council on the Future of Human Enhancement
Slidedeck supporting session held during the 2017 SharpBrains Virtual Summit: Brain Health & Enhancement in the Digital Age (December 5-7th). Learn more at: https://sharpbrains.com/summit-2017/
Patients should be able to trust their doctors blindly. However, for most of the masses getting a second opinion is has become a necessity. A doctor, albeit a human, should be able to guarantee their diagnoses of the patient. With the current advancements of technology, it is shocking that technology is not being utilized to give this guarantee. Technology is present and ever evolving to remove human error.
Thus, with the aim of using new technologies such as deep learning and neural networks, our team is developing a way to assist doctors in their diagnoses by analysing chest x-rays. Chest x-rays show a number of diseases including heart and lung issues, fluid vessels and airways. Our software based solution, will be able to analyse chest x-rays and mark any abnormalities found thereby pointing towards the correct diagnoses and improving a doctors’ efficiency in diagnoses.
The document provides an overview of a company called Miroculus that has developed an accurate, easy to use, and affordable microRNA detection platform. Some key points:
1. Miroculus has 4 full-time employees and has labs in Heidelberg and an office in Mexico City. They are developing a platform to detect circulating microRNAs which can be diagnostic biomarkers for diseases like cancer.
2. Their platform includes an accurate bioassay that can detect microRNAs from plasma samples, a low-cost device to run the bioassay, and data analytics algorithms. This allows quantitative and qualitative molecular monitoring for disease in a simple and affordable way.
3. They have prototypes of the bioassay,
NeuroPsyCAD is an AI-based platform that analyzes brain scans to provide early and accurate diagnoses of neuropsychiatric disorders like Alzheimer's and Parkinson's. By sending brain scans to NeuroPsyCAD, clinicians receive a report within hours comparing the scan to a patient database and indicating the most likely diagnosis and its probability. This allows for earlier treatment and management of diseases, slowing their progression and reducing healthcare costs compared to traditional diagnostic methods. NeuroPsyCAD has been shown to be over 50% more accurate than expert clinicians in identifying some conditions like Alzheimer's from brain scans alone.
Theranos presented to investors with the goal of becoming the standard for improving drug therapies. Its initial market is phase IV clinical trials, using a product platform of cartridges, readers, and informatics services. Founded in 2003 with 50 employees, Theranos aims to generate $120-300M in revenue over 1.5 years through deals with pharmaceutical companies. The company's system allows for simultaneous quantitative measurement of drugs and biomarkers from small blood samples, returning results comparable to gold standards within 30 minutes. Theranos' value proposition is improving drug labels and safety by enabling real-time pharmacokinetic and pharmacodynamic monitoring during trials and treatment.
Applying NLP to Personalized Healthcare - 2021David Talby
Dr. David Talby discusses applying natural language processing (NLP) to personalized healthcare. He covers how state-of-the-art NLP accuracy has recently improved for tasks like clinical named entity recognition and relation extraction but that real-world solutions require specialized models optimized for domains, languages, entities, and relations. Hyper-specialized models are needed due to the complexity of clinical text.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
The document summarizes updates on corneal cross-linking (CXL) technology from Avedro, including:
1) In March 2015, Avedro received a letter from the FDA requesting further information about equivalency between study devices and commercial systems for CXL to treat keratoconus and ectasia.
2) Agreement was reached on additional measurements required to address the FDA's questions. The application was resubmitted in October 2015.
3) Preliminary data is presented on trials of a new CXL technique called PiXL for treating myopia, keratoconus, and post-cataract refractive error, showing safety and efficacy.
From an Olympic-sized thought-powered light show to your very own brain sensing headband, InteraXon CEO and neuroscientist Ariel Garten speaks to the sensor revolution and to the democratization of brain sensing technology. With the launch of their first consumer-ready product, Muse: the brain sensing headband, Ariel shares how more and more people are turning to brain sensing tech to gain immediate insight and personalized data to track and explore their inner technologies and enable them to do more with their minds than they ever thought possible.
• Ariel Garten - Co-Founder and CEO, InteraXon
New York eHealth Collaborative Digital Health Conference
November 18, 2014
The document discusses developing new radiotracers for positron emission tomography (PET) imaging using green fluorescent protein (GFP) technology. This allows for fast, multi-platform synthesis of short-lived radiotracers for indications like pediatric neuroblastoma and Parkinson's disease. Initial targets are developing the methodology, understanding regulatory processes, and conducting animal and clinical studies. The business model involves selling radiotracers and precursors to radiopharmacies, hospitals, and imaging centers.
Commendo research & consulting GmbH proposes a recommender technology to optimize the drug design process. The technology would speed up development, allow for highly customized drugs, minimize adverse reactions, and increase the probability drugs pass clinical trials. It discovers harmful drug combinations to reduce side effects. There is a large business opportunity in the pharmaceutical industry as developing one drug costs over $800 million and 95% of drugs are rejected. The technology builds an holistic model integrating substance and effect data from all drug development stages. It uses recommender algorithms to predict unknown effects and identify substances with desired effects to develop customized drugs. The company's team previously led the Netflix Prize competition in recommender systems research.
The document proposes developing an affordable portable ultrasound device to enable widespread screening. It would benefit patients through early detection and be convenient for doctors to use like a stethoscope. The founders aim to market the device to various medical specialties. It outlines the product, team, sales strategy, target customers, costs, revenue projections, potential partners, funding needs, and risks. The goal is for the device to become profitable within 4 years of development and regulatory approval.
RM Genetics specialists work with healthcare providers to help them to determine individuals who would benefit from PGx treatment. We partner with labs acroshs the United States to offer the most progressive, gene panel testing in pharmacogenomics. We also have another program testing for hereditary cancer and toxicology. PGX test will provide a comprehensive report based on an individual patient’s genetic makeup that will indicate metabolic rates for defined medications. This information will help clinicians prescribe the right drug at the right dose based on your patient’s DNA profile.
Presentation/demo held at Google Developer Group Oslo DevFest 2014
Abstract:
This talk will show you how to build an Android Wear app. Thomas will start out with a plain notification and show you how to add features until you have a full-fledged card UI. We will discuss the role of the phone and the watch and how to communicate between them. As a case study he will use a prototype for a news alert app he's working on - there will be plenty of code examples and demos.
Thomas Oldervoll has worked 5 years for Google in Mountain View and 9 years for Zenior in Oslo. He likes building things, in particular machine learning, scalable backend systems and Android apps.
The document provides an overview of Android Wear development including basic setup, notifications, layouts, the data layer, and a comparison to WatchKit. It discusses debugging over Bluetooth, using emulators, packaging structures, basic and expanded notifications, backgrounds, remote control, actions, and common layouts. Code examples and resources are provided for key topics like notifications, data transfer, and common UI structures in Android Wear.
Android Wear is Google's attempt to bring unity to the wearable device ecosystem by optimizing Android for wearables. It allows wearables like the Moto 360 and G Watch to provide contextual information, integrate with Google services, offer better health and fitness experiences, and control other devices through features like voice actions and APIs that access device sensors. While competitors include Pebble, Galaxy Gear, and Sony SmartWatch, Android Wear differs in having no device lock-down, supporting native Android development, and using wearables as less intrusive ways to share information and naturally control other technologies.
The document discusses the self-concept, which is one's view of oneself and one's qualities. The self-concept is multidimensional, including the physical, spiritual, social, and inner selves. It is influenced by factors like skills, parents, social contact, and self-motivation. The self-concept can be positive if one evaluates one's qualities positively, or negative if one is dissatisfied. Maintaining a positive self-concept involves self-care, caring for others, positive self-talk, goal-setting, and self-reflection.
In this session, I will give an overview of Android Wear and how to integrate it in your product strategy. We will look at the underlying design principles and discuss a number of use cases for apps that connect to wearable devices. After that, we will take a look at some code examples and learn how to use the Android Wear SDK.
This document provides an overview of Android Wear and how to develop apps for it. Some key points include:
- Android Wear allows developers to extend existing Android notifications and apps to smartwatches.
- Notifications on Android Wear can include additional content, voice input, and actions.
- Apps need to be designed for quick interactions with minimal taps or swipes on small screens.
- The Android Wear SDK allows communicating between phone and watch apps using APIs for nodes, messages, and shared data.
Smartwatches have evolved from simple devices that displayed limited information like calendars and phone connectivity to full-fledged computers on the wrist. Early smartwatches in the 2000s had basic features while models in the 2010s could make calls, send texts, access the internet, and track health data. Modern smartwatches often use touchscreens, pair with smartphones for full functionality, and focus on fitness tracking and health monitoring. Top brands today include Android Wear watches and upcoming models like the Apple Watch, with pricing ranging from $100 to $400. However, smartwatches have yet to achieve mass popularity due to issues with size, battery life, and being perceived more as tech devices than fashion accessories.
Appian Medical Investor Presentation: September 2014Appian Medical
The document describes SnoreSounds, a smartphone app and algorithm that can accurately diagnose obstructive sleep apnea (OSA) using acoustic analysis of snoring sounds. It has the potential to disrupt the sleep diagnostics market by providing an inexpensive, convenient home test. Clinical studies show the algorithm achieves over 90% accuracy compared to in-lab polysomnography tests. The business model involves direct-to-consumer sales of the app as well as licensing the algorithm to partners. Regulatory clearance is underway to allow diagnosis and treatment based on the app results.
Top Brainnovation to improve Brain Health & PerformanceSharpBrains
The three Finalists were:
*Click Therapeutics — pitch by David Klein, Co-Founder & CEO
*AUGMENTx (WINNER) — pitch by Dr. Albert Kwon, Co-Founder & CEO
*Sincrolab — pitch by Ignacio de Ramon, Co-Founder & CEO
*Judged by: Alexandra Morehouse, Chief Marketing Officer at Banner Health; Colin Milner, Founder and CEO of the International Council on Active Aging (ICAA); Danny Dankner, CEO and Co-founder of Applied Cognitive Engineering; Zack Lynch, General Partner at JAZZ Venture Partners
*Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains
*Sarah Lenz Lock, Senior Vice President for Policy at AARP and Executive Director of the Global Council on Brain Health (GCBH)
*Dr. April Benasich, Director of the Baby Lab at the Rutgers Center for Molecular and Behavioral Neuroscience
*Chaired by: Dr. Cori Lathan, Co-Chair of the World Economic Forum’s Council on the Future of Human Enhancement
Slidedeck supporting session held during the 2017 SharpBrains Virtual Summit: Brain Health & Enhancement in the Digital Age (December 5-7th). Learn more at: https://sharpbrains.com/summit-2017/
Patients should be able to trust their doctors blindly. However, for most of the masses getting a second opinion is has become a necessity. A doctor, albeit a human, should be able to guarantee their diagnoses of the patient. With the current advancements of technology, it is shocking that technology is not being utilized to give this guarantee. Technology is present and ever evolving to remove human error.
Thus, with the aim of using new technologies such as deep learning and neural networks, our team is developing a way to assist doctors in their diagnoses by analysing chest x-rays. Chest x-rays show a number of diseases including heart and lung issues, fluid vessels and airways. Our software based solution, will be able to analyse chest x-rays and mark any abnormalities found thereby pointing towards the correct diagnoses and improving a doctors’ efficiency in diagnoses.
The document provides an overview of a company called Miroculus that has developed an accurate, easy to use, and affordable microRNA detection platform. Some key points:
1. Miroculus has 4 full-time employees and has labs in Heidelberg and an office in Mexico City. They are developing a platform to detect circulating microRNAs which can be diagnostic biomarkers for diseases like cancer.
2. Their platform includes an accurate bioassay that can detect microRNAs from plasma samples, a low-cost device to run the bioassay, and data analytics algorithms. This allows quantitative and qualitative molecular monitoring for disease in a simple and affordable way.
3. They have prototypes of the bioassay,
NeuroPsyCAD is an AI-based platform that analyzes brain scans to provide early and accurate diagnoses of neuropsychiatric disorders like Alzheimer's and Parkinson's. By sending brain scans to NeuroPsyCAD, clinicians receive a report within hours comparing the scan to a patient database and indicating the most likely diagnosis and its probability. This allows for earlier treatment and management of diseases, slowing their progression and reducing healthcare costs compared to traditional diagnostic methods. NeuroPsyCAD has been shown to be over 50% more accurate than expert clinicians in identifying some conditions like Alzheimer's from brain scans alone.
Theranos presented to investors with the goal of becoming the standard for improving drug therapies. Its initial market is phase IV clinical trials, using a product platform of cartridges, readers, and informatics services. Founded in 2003 with 50 employees, Theranos aims to generate $120-300M in revenue over 1.5 years through deals with pharmaceutical companies. The company's system allows for simultaneous quantitative measurement of drugs and biomarkers from small blood samples, returning results comparable to gold standards within 30 minutes. Theranos' value proposition is improving drug labels and safety by enabling real-time pharmacokinetic and pharmacodynamic monitoring during trials and treatment.
Applying NLP to Personalized Healthcare - 2021David Talby
Dr. David Talby discusses applying natural language processing (NLP) to personalized healthcare. He covers how state-of-the-art NLP accuracy has recently improved for tasks like clinical named entity recognition and relation extraction but that real-world solutions require specialized models optimized for domains, languages, entities, and relations. Hyper-specialized models are needed due to the complexity of clinical text.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
The document discusses the use of personal digital assistants (PDAs) in healthcare settings like emergency departments. It covers the growth of PDA use, their clinical uses like accessing drug references and patient records, and how they can help minimize medication errors. It also provides an overview of different PDA operating systems, factors to consider when selecting a PDA, and options for integrating PDAs with electronic medical record systems.
Meaningful (meta)data at scale: removing barriers to precision medicine researchNolan Nichols
Randomized controlled trials (RCTs) are the gold standard for evaluating therapeutics in patient populations. The data collected during RCTs include a wealth of clinical measures, biomarkers, and tissue samples – the analysis of which can lead to the approval of new medicines that improve the lives of patients. The secondary use of these data can also fuel the discovery of novel targets and biomarkers that support precision medicine, but a lack of metadata standards creates substantial barriers to reuse.
For this talk, I will discuss the challenges that arise when aggregating diverse types of data from a large number of RCTs and present a case study in how to apply (meta)data standards for the scalable curation and integration of these data into an analysis ready form.
The document discusses a mobile application-based solution for improving clinical trial data collection. It aims to significantly improve data quality while decreasing costs by collecting patient-reported outcomes and physiological data through mobile devices. This allows for more flexible trial protocols, real-world evidence collection, and improved compliance monitoring compared to traditional trials. The solution offers customized mobile apps, questionnaires, and data collection for each trial protocol while ensuring regulatory compliance and data security.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
This document summarizes the progress and findings of Team 12 in developing a drug to treat or prevent chemotherapy-induced peripheral neuropathy (CIPN). Through interviews with 104 people, including physicians, academics, and pharmaceutical companies, the team validated that CIPN is a significant problem with no fully effective treatments. Experts said prophylaxis would be valuable and phase 1 efficacy is possible. The team identified the need for preclinical data on nerve function and relevant cancer types. Pharmaceutical companies indicated interest in preclinical assets for $10M and phase 1 programs for $50-100M. The team plans to submit a grant for preclinical/safety studies and future clinical trials to generate the necessary data.
This document discusses the importance and various applications of artificial intelligence in the pharmaceutical industry. It begins with an introduction from Dr. Ruchi Tiwari on the uses of AI in R&D, drug development, diagnosis, disease prevention, epidemic prediction, remote monitoring, manufacturing, and marketing. The rest of the document provides more details on each of these areas, including examples of companies using AI for drug discovery, clinical trials, adherence monitoring, and data analysis. It also discusses challenges to AI adoption in pharma such as unfamiliarity, lack of infrastructure, and unstructured data formats. The overall message is that AI has great potential to improve efficiency and outcomes across the pharmaceutical industry.
This document discusses outsourcing in clinical trials and how it can affect risk, cost, and outcomes. It examines different categories of risk in drug development like efficacy, safety, regulatory approval, and commercial assumptions. While outsourcing aims to reduce costs and access expertise, sponsors often report worse quality than in-house after several years. Specialized providers are important for data analysis but quality must be prioritized over price. Outsourcing can help manage workload flexibility but sponsors need to carefully model assumptions and scrutinize every step of the process.
Malcolm Pradhan on Pathology in Clincial Decision Support and the role of Dee...Cirdan
Pathology testing plays an important role in the management of complex patients. Pathology laboratories continue to improve the speed and accuracy of result reporting, however the clinical management of pathology remains challenging: there is well documented variation in ordering practices, slow take-up of order sets, and up to 40% of pathology tests are not reviewed by clinical staff. The inefficient clinical utilization of pathology is a significant cost, both directly and through increased patient length of stay in hospital.
One of the established ways to improve health care delivery is integrated clinical decision support (CDS). Malcolm discusses how the effective implementation of CDS for pathology results can improve clinical productivity and patient safety. Looking further ahead the challenge for health care is to develop models of care that better tailor decisions to the needs of individual patients, and technology is required to achieve this goal. He gives a high level overview of recent advances in technology, such as big data analytics and deep learning, that will be vital in creating a sustainable health care system.
This document outlines the business plan for StressTest, a device that measures cortisol levels through sweat in real time using microfluidics and nanotechnology. It is a lower cost alternative to traditional serum cortisol tests. The business model involves direct-to-consumer sales, sales to medical professionals, and data licensing. Marketing strategies over 2015-2016 include a Kickstarter launch, content marketing, and community outreach. Financial projections estimate revenues of $1 million in 2016 growing to $4 million by 2018.
Similar to brainbackupspitchdeckversion0-150209162854-conversion-gate01 (20)
2. info@BrainBackups.com
Our Name - Brain Backups
High-Resolution Brain Imaging Platform
Nondestructive, noninvasive, whole brain in vivo imaging at the connectome level
Current methods for whole brain imaging
● Current methods of whole brain in vivo imaging do not provide adequate resolution.
● Methods providing adequate resolution have incomplete coverage, or require
destructive slicing of the brain.
First Target: An Early & Accurate Parkinson’s Disease Diagnostic
4. info@BrainBackups.com
The Solution - AptaMark
Accurate & Objective
Dopamine D2R test
AptaMark will be the first contrast agent with a single
cell resolution, allowing neurodegeneration in the
substantia nigra and other relevant areas can be tracked
objectively.
• First Objective Diagnostic for PD
• Enables early detection
• Tracks degradation directly at source
• Differentiates amongst PD subtypes
• Non destructive/non invasive
• 1 micron resolution
5. info@BrainBackups.com
● 34 drugs in development
● Aging population
● $26B in US Healthcare Costs
● $3B in PD specific treatment
“Large potential market for neurotechnology”
- NeuroTech Business Report
The Opportunity
PD diagnosis and mid-treatment imaging demand will
continue to grow.
6. info@BrainBackups.com
Competitive Analysis
Cost Accuracy Early
Detection
Objectivity Resolution
Doctors Low ~76% Clinical No N/A
Movement
Software
$100 Low Clinical Yes N/A
CT $700 Moderate Clinical No 1mm
MRI $1,200 ~85% Clinical No 1mm
DaTscan $5,000 ~84% Clinical No 1mm
AptaMark $2,800 Aim >90% Preclinical Yes 1µm
7. info@BrainBackups.com
The Competitors
New contrast agents are being developed every year.
All lack the specificity of AptaMark and many rely on expensive small molecule chemistry &
approvals process and often less precise methods.
DaTscan is a SPECT iodine-123 contrast agent that
images dopamine transporter and allows clinicians to
distinguish essential tremor from PD.
AptaMark permits imaging at 1 micron resolution,
100X better than MRI; offers specificity to subtypes
of dopamine receptors; uses same GE imaging
hardware provides better diagnosis.
8. info@BrainBackups.com
Revenue Projections
Assuming a 5% market share in Y4, we can reasonably expect close to
$4M per year in initial diagnostic revenue.
If AptaMark is used in treatment management, revenue growth becomes exponential.
40,000 out of 1.5M total patients tested twice a year will result in $100M of revenue.
Market Share RevenueCost per Test
As costs decrease with scale, EBITA will grow from
11% to more than 48% as quantity grows past 1000.
9. info@BrainBackups.com
Potential Partnerships
From MRI to aptamers, a lot of companies work with relevant
technology. We are continuing an active outreach process to
engage researchers and clinicians alike with our technology.
11. info@BrainBackups.com
...to demonstrate Parkinson’s can be imaged at the source.
● $2.5M for further optimization & research deployment
● Potentially positive ROI from research revenue alone
● $30M+ for Phase I & Phase II toxicology trials
● Exit after proven safety & efficacy
● Clinical trials performed through partnerships
What we are asking for...
12. info@BrainBackups.com
30,000 Validation and Optimization 1.2%
20,000 Scale up batches 0.8%
50,000 At scale batches 2%
400,000 Real estate: laboratory & office space 16%
250,000 Main laboratory equipment 10%
500,000 In vivo validation FDA 510K 20%
100,000 Licensing to established vendors 4%
1,100,000 Personnel and marketing 44%
50,000 To be budgeted and incidentals 2%
Total:
2,500,000 100%
Appendix: Financial I - $2.5M Series A Breakdown
13. info@BrainBackups.com
Appendix: Financial II - Research Revenue
Core product is a recurring cost consumable
● Initial product cost*: $1,300/test
● Scale product costA: $550/test
● Cost to consumer: $2,800/test
● Break-even point T: ~1,200 tests
● Assuming an MRI cost of ~$1,000, AptaMark is competitive with DaTscan
for diagnostic and treatment management imaging
● Even with 80% production profit margin, AptaMark remains 100x more
rentable than current destructive research methods
A Cost estimates are for total cost of production, manufacturing, and overhead at appropriate stage
* Assumes 200+ test batches T At scale cost, associated profit margin, and 2.5M Series A
15. info@BrainBackups.com
Appendix: Financial III - Ancillary Markets
Research Products
● Alzheimer’s
● Autism
● Huntington’s
● Schizophrenia
● Additional research
● Obsessive Compulsive Disorder
● Etc...
16. info@BrainBackups.com
Appendix: Science I - About Aptamers
Advantages of Using Aptamers
● Very small, very precise ~ 1 micron
● Chemically synthesized, no bioreactors
● Easy to ship, safe to handle
● Cross blood brain barrier
● Don’t trigger the neurons they bind to
● Safely cleared
17. info@BrainBackups.com
Appendix: Science II - Technology Details
Gold nanoparticle with attached D2-specific ligand
Rat knee imaged at 3 microns (0.003mm voxel)
Nanoparticle uniformity validation using dynamic light
scattering
http://www.caringfortheages.com/news/geriatric-medicine/single-article/how-to-avoid-the-most-common-diagnostic-pitfalls-for-parkinson-s/9887e4762644a0fac594c98b26445af7.html
Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes jnnp.bmj.com/content/early/2013/03/12/jnnp-2012-304436.full.pdf
the only real - objective diagnostic is post-mortem
how does it undercut current research cost
what is current research cost
say $1300 per treatment - millions for slicing ad imaging, never been done due to cost
Monogenic disease, so diagnostic is already done and much cheaper
For autism - check out C-Side therapeutics (contact CEO, Randy Carpenter)
Gross macro level current diagnosis for Parkinson’s - we should look at getting a more granular look
Market background for our MJ Fox proposal, same for Huntington’s Research Center
1/20 patients with Parkinson’s is misdiagnosed - real opportunity to improve management of patients
Consequences for how early treatment
Allison: For an investor pitch, this slide will probably be in the appendix. You should have what your product does in the solution slide. You can go into further detail in the appendix if someone asks, but more likely than not, investors do not want the niddy griddy of what you can do. You should be able to describe what you do and why you add value to your market in 1 slide. Find a way to be concise and clear for the investors.
76% conflicts with slide 2
in 40 years of research no diagnostic has gotten to 90% accurate
Imaging Approaches to Parkinson Disease
jnm.snmjournals.org/content/51/4/596.fulte
Add a graphic for Avid - imaging area for disease
Biologic Imaging Reagents: Technologies and Global Markets Report
http://www10.giscafe.com/nbc/articles/view_article.php?articleid=735344&page_no=3
http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle&id=1881352
Iodine-123 labeled NAV5001 is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The agent binds to the dopamine transporter (DAT) on the cell surface of dopaminergic neurons in the striatum and substantia nigra regions of the brain. Loss of these neurons is a widely recognized hallmark of Parkinson’s disease and other forms of Parkinsonism.
Lantheus - isotope producer: already in the space, lower resolution
Nanoprobes - nonspecific agent to provide brain imaging
Nanosphere - maybe like nanoprobes
Allison: If you can put this in a competitive landscape graph or a comparison chart. It is easier to read and see right off the bat how you are better than the competitors.
180,000 people imaged using DaTSCAN to date
https://www.michaeljfox.org/files/Imaging%20FAQ%20Sheet%20for%20Patients.pdf
The FDA has approved a new neuroimaging agent that offers nonspecialists the possibility of differentiating parkinsonism from essential tremor (ET).
http://www3.gehealthcare.com/search?q=datscan%20&u=http://www3.gehealthcare.com/en#
What are the kind of partners?
Marketing? Exit?
What’s your business model?
What’s your product strategy?
Existing relationships with end customers
More efficient to go through them in the short term before building an inhouse sales team
Fewer distributors: show a relationship or envisaged one and the way it would work
Logos of Companies you worked at
Titles - Maybe
Value
End with the ask
Money to exclusively license all the ligands - $ up front
Technology license
Ask questions around the value proposition?
How do we intend to position this? What will we actually ask a customer for?
This is for clinical uncertainty Vs This is for unresponsive therapy
Where do we carve out a niche initially and where can we expand to from a longer point standpoint with sequenced growth.
IF we go into a hospital this is who we talk about: do we see physicians? Key opinion leaders? PD clinics or other focused dept?
Pick your sweet spot?
Are hospitals making money on DaTscan? Reimbursement amounts?
Define the buying process, talk to some buyers in hospitals, opinion leaders in movement disorder clinics, follow the money and show where it comes in and where our leverage points are
Scaling over time: where we’re going to be?
EBITA there
Allison: Do you have other revenue streams outside the “core product”? Can you put this in a graph or timeline or something?
What is that partnership? To sell the drug?
IP Status snapshot
Patent panel of aptamers
computational analysis piece around series C - IPO
Capitalize Tranche
make “profitablity line” a different color than Start/seed
Change for DIAGNOSTIC
Series A -
Problem with Huntington’s - monogenic disease - price for gene sequencing is going through the floor
Therapies currently don’t work very well. Nothing that is immediately available.
Follow up with Daniel - therapies
Tetrabenazene - no one knows exactly what target we should be identifying
MRI in diagnosing MS - look further into usage
GE launched MRI - PET machine 2 weeks ago - combined machine is interesting
Imaging companies jump in after proof of concept is done
MGH/GE/BB partnership potential for development & application
VC arms of large pharma (Pfizer, etc)
GE Antaries - GE Ventures arm - GE Healthcare group
What do we offer a partner?
What exactly is the business model we would propose to GE?
Would it only work no GE machines? Analytics/Software - GE MRI API
Deliverable framed as a quid pro quo for their API
GE is the only one that has the resolution that we need to make this work
Make two slides about why there is an opportunity for GE
Look up UCB - does research in epilepsy, TBI, stroke
Deal with Oxford on imaging
UCB - aggressive program to identify imaging opportunities for potential drug development
Merck - imaging
Eli Lilly - bought Avid & doing research in Alzheimer’s
Supernus - Company in UK doing research in Epilepsy
Abbott - fair amount of imaging (PET)
Janssen - GsK - neuroimaging work
Janssen neuroscience innovation center in Cambridge - Jeff Nye head of initiative
Market snapshot in its current form, number of patients, market share, revenues, overlays the impact of what our technology would be
patient provider relationships, research relationships, partnerships, etc
What this would look like tomorrow given what we can do?
MGH head of neuroscience - Tom Brady
A lot of facilities are losing medicare reimbursement for imaging
Not that easy to read a paper and go recreate what was published
Neurotechinsights.com
Focus on Parkinson’s is on remission
Allison: You could do the Market slide and market growth in 1 slide. Have the overarching market, then the target market first and then how the market can grow.
The partnerships and other institutions that you are working with, I would put those in a different slide after the revenue. You have a bunch of institutes in the market slide, are those partnerships? Who are they? If they are partnerships, I would put them in a separate slide and place that slide after revenue. so you can say here is how we are going to make money, and then these partnerships will be how we execute the plan to make money.
Is there some data we could show?
What drove the hypothesis, how we’re going to test it?
how does it undercut current research cost
what is current research cost
say $1300 per treatment - millions for slicing ad imaging, never been done due to cost
Monogenic disease, so diagnostic is already done and much cheaper
For autism - check out C-Side therapeutics (contact CEO, Randy Carpenter)
Gross macro level current diagnosis for Parkinson’s - we should look at getting a more granular look
Market background for our MJ Fox proposal, same for Huntington’s Research Center
1/20 patients with Parkinson’s is misdiagnosed - real opportunity to improve management of patients
Consequences for how early treatment
Allison: Is this part of your competitive comparison how your product is better because you use aptamers? Again, I would put this in the appendix in case an investor asks for further detail. Again though, investors typically want to know the high overview and understand but don’t need the details.
Movie reconstruction from human brain activity
https://www.youtube.com/watch?v=nsjDnYxJ0bo